Search results for "VAST"

Tukivastemalli (Response to intervention model)

2021

Tukivastemalli on oppimisen ja koulunkäynnin tuen suunnittelua ja toteutusta selkeyttävä toimintatapa, jota voidaan hyödyntää minkä tahansa taidon tukemisessa kolmiportaisen tuen mallin kaikilla portailla. Tukivastemallissa tuen tavoitteiden määrittely ja kohdennettu tukitoimien suunnittelu perustuvat huolelliseen, yksilölliseen alkuarviointiin oppilaan tuen tarpeesta ja ymmärrykseen siitä, mistä oppilaan yksilöllisissä oppimisen pulmissa on kyse. Tuki kohdistetaan siihen kehitysvaiheeseen, jossa oppilas kehityksellisesti on ja niihin osataitoihin, joissa oppilaan kehitys edellyttää tukea. Oppimisen tuen suunnittelun yhteydessä suunnitellaan, miten ja kuinka usein oppimisen edistymistä ja t…

Risperidone and severe cerivastatin-induced rhabdomyolysis

2002

Visual hallucinations and agitation in Alzheimer's Disease due to memantine: report of three cases

2007

Memantine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, is currently the only drug proposed for the treatment of moderate to severe Alzheimer’s disease.1 It has been shown to have neuroprotective effects by inhibiting the excitotoxic effect of NMDA glutamate receptors.2 Memantine has a tolerability profile similar to placebo.1 However, the worsening of psychotic symptoms in patients with Lewy body dementia (LBD) treated with memantine has been recently reported.3 We describe three patients with probable Alzheimer’s disease who developed worsening or de novo visual hallucinations and agitation after memantine treatment. Patient 1 was a 65-year-old woman with a 2-year hi…

Von der symptomatischen zur kausalen Therapie?

2009

Until today the pharmacological therapy of Alzheimer’s disease (AD) is still limited to symptomatic temporary improvement or stabilization of cognitive performance and activities of daily living, and the reduction of neuropsychiatric symptoms of the disease. Available symptomatic treatment options are the acetylcholinesterase inhibitors (ACh-I) donepezil, galantamine, rivastigmine, and the partial N-Methyl-D-Aspartat-(NMDA)-antagonist memantine. Further substances with symptomatic targets, especially selective acetylcholine and histamine receptors, are currently under development. Numerous of disease-modifying substances mainly targeting components of the amyloidogenic pathway of AD are pre…

2021

Four drugs are currently approved for the treatment of Alzheimer’s disease (AD) by the FDA. Three of these drugs—donepezil, rivastigmine, and galantamine—belong to the class of acetylcholine esterase inhibitors. Memantine, a NMDA receptor antagonist, represents the fourth and a combination of donepezil and memantine the fifth treatment option. Recently, the gut and its habitants, its microbiome, came into focus of AD research and added another important factor to therapeutic considerations. While the first data provide evidence that AD patients might carry an altered microbiome, the influence of administered drugs on gut properties and commensals have been largely ignored so far. However, t…

Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR

2000

Galantamine (ReminyI ) is a novel drug treatment for mild to moderate Alzheimer's disease (AD). Originally established as a reversible inhibitor of the acetylcholine-degrading enzyme acetylcholinesterase (AChE), galantamine also acts as an allosterically potentiating ligand (APL) on nicotinic acetylcholine receptors (nAChR). Having previously established this second mode of action on nAChRs from murine brain, we demonstrate here the same action of galantamine on the most abundant nAChR in the human brain, the α4/β2 subtype. This nAChR-sensitizing action is not a common property of all, or most, AChE inhibitors, as is shown by the absence of this effect for other therapeutically applied AChE…

Erythematous maculopapular eruption due to rivastigmine therapy

2001

"Eihän tätä ole olemassakaan" : tunnustamattomuus, kirjoittaminen ja kuolema Pirkko Saision teoksissa Pienin yhteinen jaettava, Vastavalo ja Punainen…

2009

"Todellisuus on lause, jonka kirjoitan" : omaelämäkerrallinen ja fiktiivinen kerronta sekä minuuden kerrokset Pirkko Saision teoksissa Pienin yhteine…

2005

Heteroaromatic Inhibitors of the Astacin Proteinases Meprin α, Meprin β and Ovastacin Discovered by a Scaffold-Hopping Approach.

2020

Abstract Astacin metalloproteinases, in particular meprins α and β, as well as ovastacin, are emerging drug targets. Drug‐discovery efforts have led to the development of the first potent and selective inhibitors in the last few years. However, the most recent compounds are based on a highly flexible tertiary amine scaffold that could cause metabolic liabilities or decreased potency due to the entropic penalty upon binding to the target. Thus, the aim of this study was to discover novel conformationally constrained scaffolds as starting points for further inhibitor optimization. Shifting from flexible tertiary amines to rigid heteroaromatic cores resulted in a boost in inhibitory activity. …